<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">
Logo Kérwá

Occurrence and risk assessment of pharmaceuticals in hospital wastewater in Costa Rica

Cargando...
Miniatura

Fecha

Authors

Rodríguez Rodríguez, Carlos E.

Ramírez Morales, Didier Daniel

Masís Mora, Mario Alberto

Montiel Mora, José Rolando

Soto Garita, Claudio

Araya Valverde, Emanuel

Cambronero Heinrichs, Juan Carlos

Sànchez Melsió, Alexandre

Briceño Guevara, Susana

Méndez Rivera, Michael

Título de la revista

ISSN de la revista

Título del volumen

Editor

Resumen

This work aims to determine the occurrence, hazard and prioritization of pharmaceuticals from hospital wastewater in Costa Rica through the monitoring of 70 compounds and assessing their environmental risk through a hazard quotient approach (HQ). Moreover, the quantification of selected antibiotic resistance genes (ARGs) was conducted for the first time in this matrix in this geographical location. Thirty-four pharmaceuticals were detected, being caffeine, 1,7-dimethylxanthine, acetaminophen, ibuprofen, naproxen, ciprofloxacin and ketoprofen the most frequent (>50% of the samples). Eighteen pharmaceuticals exhibited high hazard (HQ ≥ 1), while five more showed medium hazard (1 > HQ ≥ 0.1). Prioritization, which also included frequency parameters, revealed caffeine, lovastatin, diphenhydramine, acetaminophen, ibuprofen, ciprofloxacin, and sildenafil as the compounds of major concern. Similarly, cumulative hazard per sample (ΣHQ) estimated high hazard towards aquatic organisms in every sample. All selected ARGs, except mcr-1 (polymyxin resistance), were detected. Among genes conferring resistance to beta-lactams, blaCTX-M and blaKPC were the most abundant, related to resistance to cephalosporins and carbapenems. Ecotoxicological evaluation showed mostly low toxicity towards Daphnia magna and Vibrio fischeri, contrary to the marked effect observed towards Lactuca sativa. These findings provide relevant and novel information on the risk posed by hospital wastewater and their pharmaceutical content in the Latin American environmental context.

Descripción

Aprobación

Revisión

Complementado por

Referenciado por

Rights and licensing

acceso abierto